Lilly Acquires AtaiBeckley to Advance Depression Therapies
INDIANAPOLIS and NEW YORK, July 16, 2026 Eli Lilly and Company has announced a definitive agreement to acquire AtaiBeckley...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
INDIANAPOLIS and NEW YORK, July 16, 2026 Eli Lilly and Company has announced a definitive agreement to acquire AtaiBeckley...
NEW YORK, July 6, 2026 AtaiBeckley Inc. announced that the final patient has been dosed in Elumina, its international...
